EUVIMEDEUVIMED entdecken
Crossref

Mitochondrial Metabolic Reprogramming along with NRF2/KEAP1-Mediated Antioxidant Mechanisms Drive Temozolomide Resistance in Glioblastoma Multiforme

Manendra Singh Tomar iD, Chirag Kulkarni, Kaveri R Washimkar, Shobhit Verma, Amita Bhadkaria, Fabrizio Araniti iD, Madhav Nilakanth Mugale iD, Naibedya Chattopadhyay iD, Ashutosh Shrivastava

Journal of Proteome Research · 02.01.2026 · 25 (1) · 379-394

DOI: 10.1021/acs.jproteome.5c00734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Proteome Research, online erschienen am 05.12.2025. Verfasst von Manendra Singh Tomar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow-226003, Uttar Pradesh India. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, NF-E2-Related Factor 2, Kelch-Like ECH-Associated Protein 1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, University Grants Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temozolomide (TMZ) is a frontline chemotherapeutic agent for glioblastoma multiforme (GBM); however, approximately half of patients develop resistance to therapy. This study investigates the role of altered cellular bioenergetics and metabolism in the acquired TMZ resistance. Using untargeted metabolomics, we explored the metabolic rewiring in TMZ-resistant GBM cells and identified key alterations in glycolysis, the tricarboxylic acid (TCA) cycle, fatty acid metabolism, and amino acid metabolism, all might be linked to cellular proliferation. Our findings suggest that while glycolysis remains important, increased TCA cycle activity contributes to the drug resistance, supported by increased levels of mitochondrial mass and mitochondrial membrane potential. We observed significantly elevated glutamine levels, which may enhance mitochondrial activity, thereby supporting increased energy production. Furthermore, resistant cells exhibited enhanced NRF2 level in parallel with higher levels of antioxidants, including glutathione and catalase enzyme, and a concomitant decrease in the level of its negative regulator, KEAP1. These factors collectively may contribute to drug resistance by mitigating oxidative stress. These findings indicate that mitochondrial metabolic reprogramming and NRF2/KEAP1-mediated antioxidant defense mechanisms play a crucial role in TMZ resistance, and targeting these pathways may offer a novel strategy to overcome resistance in GBM therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGlioblastomaNF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1MitochondriaDrug Resistance, NeoplasmAntioxidantsHumansCell Line, TumorCitric Acid CycleOxidative StressGlycolysisAntineoplastic Agents, AlkylatingMembrane Potential, MitochondrialMetabolomicsEnergy MetabolismGlutathioneMetabolic Reprogramming

Stichwörter der Autor:innen

drug resistanceglioblastoma multiformemitochondria metabolismoxidative stresstemozolomide

Substanzen

TemozolomideNF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1NFE2L2 protein, humanKEAP1 protein, humanAntioxidantsAntineoplastic Agents, AlkylatingGlutathione

Autor:innen und Institutionen

  • Center for Advance Research, Faculty of Medicine, King George's Medical University, Lucknow-226003, Uttar Pradesh India.
  • Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), CSIR-Central Drug Research Institute, Lucknow-226031, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad- 201002, India.
  • Present affiliation: Food and Micronutrient Analysis Laboratory, KLE Academy of Higher Education and Research, Belagavi-590010, India.
  • Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow-226031, India.
  • Present affiliation: Department of Neurological Surgery, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania 15213,United States.

ORCID-Profile: Manendra Singh Tomar, Fabrizio Araniti, Madhav Nilakanth Mugale, Naibedya Chattopadhyay

Förderung

  • Council of Scientific and Industrial Research, India
  • University Grants Commission

Zitieren

APA

Tomar, M. S., Kulkarni, C., Washimkar, K. R., Verma, S., Bhadkaria, A., Araniti, F., Mugale, M. N., Chattopadhyay, N., & Shrivastava, A. (2026). Mitochondrial Metabolic Reprogramming along with NRF2/KEAP1-Mediated Antioxidant Mechanisms Drive Temozolomide Resistance in Glioblastoma Multiforme. Journal of Proteome Research, 25(1), 379-394. https://doi.org/10.1021/acs.jproteome.5c00734

Vancouver

Tomar MS, Kulkarni C, Washimkar KR, Verma S, Bhadkaria A, Araniti F, et al. Mitochondrial Metabolic Reprogramming along with NRF2/KEAP1-Mediated Antioxidant Mechanisms Drive Temozolomide Resistance in Glioblastoma Multiforme. Journal of Proteome Research. 2026;25(1):379-394. doi:10.1021/acs.jproteome.5c00734

BibTeX
@article{Tomar2026,
  author = {Tomar, Manendra Singh and Kulkarni, Chirag and Washimkar, Kaveri R and Verma, Shobhit and Bhadkaria, Amita and Araniti, Fabrizio and Mugale, Madhav Nilakanth and Chattopadhyay, Naibedya and Shrivastava, Ashutosh},
  title = {Mitochondrial Metabolic Reprogramming along with NRF2/KEAP1-Mediated Antioxidant Mechanisms Drive Temozolomide Resistance in Glioblastoma Multiforme},
  journal = {Journal of Proteome Research},
  year = {2026},
  volume = {25},
  number = {1},
  pages = {379--394},
  doi = {10.1021/acs.jproteome.5c00734}
}
Kostenlos starten →